Published in final edited form as:

J Neurooncol. 2016 September ; 129(3): 433–441. doi:10.1007/s11060-016-2188-8.

The Effects of Sequential Treatments on Hippocampal Volumes in Malignant Glioma Patients

Shantell C. Nolen^{1, #}, Brian Lee^{1, #}, Shruti Shantharam¹, Hon J. Yu², Lydia Su^{2, 3}, John Billimek^{5, 6}, and Daniela A. Bota^{1, 3, 4, *}

¹Department of Neurology, UC Irvine Medical Center

²Department of Radiology, UC Irvine Medical Center

³Chao Family Comprehensive Cancer Center, UC Irvine Medical Center

⁴Department of Neurological Surgery, UC Irvine Medical Center

⁵Health Policy Research Institute

⁶Department of Family Medicine, UC Irvine Medical Center

Abstract

Objectives—Malignant gliomas (MG) are very aggressive tumors. In an effort to improve the outcome, the patients receive multi-modal therapies such as surgery, radiation and chemotherapy (temozolomide followed in many cases by bevacizumab). The survivors are affected by multiple learning and memory deficits. Greater deterioration over time in hippocampal specific cognitive tasks was shown in patients receiving bevacizumab in addition to radiation and temozolomide for a longer period of time (RTOG 0825). The rate of hippocampal atrophy in patients treated with radiation and temozolomide followed by bevacizumab is not yet determined, and is the goal of the present study.

Methods—We used the serial MRIs obtained as parts of standard clinical care in patients with MG. Measurements were done using the Medical Image Processing, Analysis and Visualization (MIPAV) software. The hippocampus in the contralateral hemisphere was manually traced and measured, to avoid morphological structure changes induced by the tumor, radiation fields or surgical markers.

Results—We determined a longitudinal progression of hippocampal atrophy – with the maximum volume loss (33.26%) for the patients that were on treatment for five years. There was

*Corresponding Author: Dr. Daniela A. Bota, UC Irvine Medical Center, 200 S. Manchester Avenue, Suite 206, Orange, CA, 92868.
#SCN and BL have equal contribution to this research. SCN and JB carried out the statistical analysis.

Author Contribution: Shantell C. Nolen: gathered data, wrote the manuscript, performed statistical analysis
Brian Lee: performed MRI measurements
Shruti Shantharam: performed MRI measurements, selected eligible patients for the study
Hon J. Yu: taught BL and SS how to performed MRI measurements, collected data, reviewed the manuscript
Lydia Su: participated in project design, critically edited the manuscript, provided imaging expertise
John Billimek: supervised and guided SCN through the statistical analysis of the data
Daniela A. Bota: formulate the project, obtained IRB approvals for gathering and analyzing the patient data, conducted the retrospective review of the patient's medical records, supervised and critically edited the manuscript.

Disclosures: The authors (Shantell C. Nolen, Brian Lee, Shruti Shantharam, Hon J. Yu, Lydia Su, John Billimek and Daniela A. Bota) have no financial relationships relevant to this manuscript. Neither of the authors has any conflict of interests.

no detectable hippocampal atrophy during the chemo-radiation followed by adjuvant temozolomide. A significant decrease in the absolute hippocampus volume was noted after 6 months of continuous bevacizumab treatment ($p<0.05$). The hippocampal volume loss progressed over the next three years, and was higher than the one previously reported in Alzheimer disease patients.

Conclusions—The hippocampal volume loss is minimal during the first months after diagnosis, when the patients receive chemo-radiation and adjuvant temozolomide. However, prolonged treatment including bevacizumab is associated with a significant rate of hippocampal volume loss.

Search Terms

malignant glioma (214); radiation (219); temozolomide (218); bevacizumab (218); and hippocampus

Introduction

Treatment advances lead to prolongation of survival for patients with high-grade astrocytic gliomas (anaplastic astrocytoma, AA and glioblastoma, GBM) and have made increasingly important to study long-term treatment related effects, including cognitive deficits. Treatments for malignant gliomas include radiation and temozolomide chemotherapy¹. However, radiotherapy can induce cognitive decline² and in extreme cases can cause dementia³. The use of temozolomide with radiotherapy enhances neurotoxicity and contributes to further cognitive deficits⁴. Bevacizumab is commonly used in patients with recurrent malignant gliomas that have failed temozolomide⁵. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)⁶. VEGF-A stimulates tumor angiogenesis, but it also promotes neurogenesis in the brain, particularly in the hippocampus, effecting fundamental processes needed for learning and memory⁷. Therefore, bevacizumab might contribute to cognitive impairment, especially in patients receiving this agent for prolonged periods of time⁸. Previous research (Bag A.K. *et al.*) suggested that high-grade glioma patients using bevacizumab experience a significant increase in ventricle volume over time as well as a significant decrease in whole brain volume and grey matter volume⁹. However, the authors were unable to segment grey matter, white matter, or hippocampus due to the poor contrast resolution of their images⁹.

Cognitive impairments in brain tumor patients resemble clinically those seen in other neurodegenerative conditions such as the mild cognitive impairment (MCI) and Alzheimer dementia (AD). The process of hippocampal atrophy (both expressed as an absolute loss of hippocampal volume, as well as the percentage of volume loss each year) is more severe in the MCI and AD patients compared to the normal population^{10, 11}. The question if similar findings can be identified in malignant glioma patients treated for long periods of time is the focus of our present article.

Methods

Patient Selection and Study Design

To be eligible for inclusion in our retrospective, Institutional Review Board (IRB) approved study, the patients needed to meet the following criteria: newly-diagnosed, supratentorial malignant glioma (GBM or AA), treated at the University of California, Irvine Medical Center's (UCIMC) Comprehensive Brain Tumor Clinic, on active treatment for at least 18 months, and on bevacizumab for at least 6 months of their clinical course, with sagittal, fine cuts 3D contrast enhanced MPRAGE T1 weighted images available at the key analysis points. The 13 patients identified had surgical resection to remove tumor after the initial diagnosis and 6 weeks of radiotherapy with concomitant temozolomide. In absence of tumor progression, the patients received post-radiation adjuvant temozolomide, and were started on bevacizumab at the time of first tumor progression. Clinical Variables for each patient are outlined in Table 1. Brain MRI's were obtained before and after surgery, two weeks after completion of radiotherapy, and every 4 to 8 weeks during the chemotherapy treatment, as clinically indicated.

MRI Methods and Image Analysis

MRI imaging was conducted concurrently with clinical appointments every 4 to 8 weeks or earlier if a patient displayed evidence of progressive disease. 1.5 Tesla and 3.0 Tesla MRIs were used to generate sagittal 3D contrast enhanced MPRAGE T1 weighted images. Of the 289 MRIs collected from eligible patients, 243 were suitable for volumetric measurement. Measurements were done using the Medical Image Processing, Analysis and Visualization (MIPAV) software by a research associate (BL) blinded to the patient treatment history, and then validated by another research associate (SS), who was independent from the first. The manual segmenting was also verified by the PI (DB). The manual tracing of hippocampal boundaries were done consecutively from the rostral to the caudal side of brain for each image. The hippocampus in the contralateral hemisphere was traced and measured, to avoid morphological structure changes induced by a tumor, shunt, radiation fields or surgical markers. MIPAV software calculates the absolute volume automatically, determined by the number of voxels in each delineated image, and a value is given in mm³.

Statistical Analysis

Patient parameters and clinical variables (Table 1) were analyzed using descriptive statistics. Primary outcome measures for this study included monthly and annual rates of hippocampal atrophy (%), as well as the longitudinal progression of the mean total atrophy. Linear regression was used to evaluate significant ($p < 0.05$) differences in hippocampal volume overtime. There were two measure outcomes, similar with the outcomes reported previously in the MCI and AD studies^{10, 11} (see also Table 2). The first outcome assessed hippocampal atrophy as a percent of total volume loss as compared with the hippocampal volume at the time of diagnosis. The second outcome calculated the rate of hippocampal atrophy using the difference in absolute volume (mm³) at each time interval. Pearson's correlation examined the homogeneity between rates of volumetric change and patient descriptives (age, tumor grade, progression time, chemotherapy duration). Paired sample T-Tests determined whether the mean rates of atrophy were significant between different time periods. Multiple

regression models assessed the effect of covariates (age, gender, tumor location, tumor grade, progression time, length of time on temozolomide, temozolomide cycles, bevacizumab duration, disease duration and survival status) on absolute and percent of hippocampal atrophy. Statistical analysis was performed using the newest version of SPSS 23.

Results

A total of 13 patients, 6 males and 7 females were identified with a mean age of 54 ± 14.183 (median= 55). Of the 10 GBM and 3 AA tumors in study, 7 were on the right hemisphere and 6 were on the left. All patients received radiotherapy with concomitant temozolomide, but 2 patients did not have post-radiation adjuvant temozolomide due to unequivocal tumor progression and were started directly on bevacizumab. For the 11 patients that received adjuvant temozolomide, the average time on adjuvant temozolomide was 8.71 months. At the first tumor progression all the patients received bevacizumab. The total duration of bevacizumab treatment for a single patient in our study ranged from 8 months to 55 months, with the overall average of 32.22 (median= 33.45) months. Median follow up time from diagnosis was 3.26 years, with 9 of the 13 patients still alive at the conclusion of the study. Median time from diagnosis to start of bevacizumab treatment was 7.86 months (34.14 weeks). The average number of MRIs measured per patient was 19.69 ± 5.67 (median= 20).

We determined that the volume of hippocampus declined in all our patients over the duration of their treatment (see Figure 1, representative patient). Figure 2 Panel A shows the longitudinal progression of hippocampal atrophy, with a maximal level of volume loss of 33.26% being reached at almost 5 years after the initial diagnosis. Figure 2 Panel B shows identical data as a function of absolute volume loss.

Hippocampal atrophy rates were also calculated separately for each step in the treatment (radiation and concomitant temozolomide, adjuvant temozolomide and bevacizumab). We did not find a significant loss of hippocampal volume from the time of diagnosis until the end of radiation and the completion of the first 5 months of adjuvant temozolomide. Figure 2 Panel C shows the longitudinal progression of hippocampal atrophy, with a modest level of volume loss of 7.07% being reached at the time of tumor progression. Figure 2 Panel B shows identical data as a function of absolute volume loss. A significance ($p < 0.05$) in percent volume was detected only at one single time point early in the treatment course (after 6 months of temozolomide treatment), but was not confirmed by the absolute volume analysis.

A significant decrease in the absolute hippocampus volume was noted after 6 months of continuous bevacizumab treatment ($p < 0.05$). A similar trend was noted also for the rate of hippocampal volume atrophy, with the statistically significant difference being detected 18 months after the start of bevacizumab ($p < 0.01$). The volume loss continued for as long as the patients received bevacizumab (Figure 2, Panel A and B). In Figure 2 Panel E we compared hippocampal volume changes at the start of bevacizumab and after 1 year, 2 years, and 3 years of bevacizumab treatment. For the patients that were able to receive three years of

continuous bevacizumab treatment (n=6), the hippocampal volume continued to decline every year.

Independent samples T-Test were then used to determine whether particular group mean differences were significant. The number of temozolomide cycles or the length of time on temozolomide did not predict either the yearly hippocampal atrophy rate ($p=0.067$), or the monthly hippocampal atrophy rate ($p=.065$). The GBM patients had higher monthly and annual rates of total and bevacizumab atrophy as compared with the AA patients ($p<0.05$). No detectable significance for gender, bevacizumab duration, or disease duration was found.

Discussion

Chemotherapeutic drugs such as temozolomide and bevacizumab have led to improved progression free survival and overall survival in patients with malignant gliomas. However, many patients exhibit patterns of cognitive impairment involving hippocampal related learning and memory paradigms (such as the Controlled Oral Word Association Test and the Trail Making Test¹²) and experience lower quality of life (QOL) – which potentially associates with prolonged bevacizumab use (such as the GBM patients who received bevacizumab from the initial diagnosis in the RTOG 0825 study)¹³. At the same time, no changes were seen in the hippocampal volumes for the GBM patients receiving standard radiation and temozolomide treatment¹⁴. Nevertheless, the Prust *et al* study followed the patients for only a short period of time (35 weeks after the initial diagnosis – less than nine months)¹⁴, while our study followed our patients for up to 6 years – which supports the hypothesis that hippocampal atrophy is a delayed effect of malignant glioma treatment. Though we cannot separate the effects of radiation and the temozolomide for the effects of bevacizumab our pilot study suggests that the hippocampal atrophy might be accelerated by long-term bevacizumab use - as our patients reached a statistically significant level of hippocampal atrophy as expressed absolute volume loss only after 6 months of bevacizumab treatment. We also did not find any measurable hippocampal atrophy when we compared the values obtained at the time of diagnosis with the post-radiation MRIs and the MRIs obtained after 6 months months of temozolomide treatment (approximately also 35 weeks after the initial diagnosis), similar with Prust's study¹⁴.

Our data are limited by the absence of control groups – patients that received only radiation and temozolomide, and did not require any other treatments for the next one to three years. We have tried to identify control MG patients with similar pathology that have survived similarly long periods of time (four or more years) without tumor progression and without receiving bevacizumab – but we were able to identify only two such patients in our large practice. In order to mitigate the effects of radiation, we measured the hippocampal volumes in the opposite side of brain then the tumor, and we made sure that the contralateral hippocampus was not affected by surgery and not included in the radiation fields.

In patients with MCI and AD, the rate of hippocampal atrophy correlates with disease progression and with the severity of cognitive loss^{10, 11} (see Table 2). The annual percent change (APC) of hippocampal atrophy in normal (1.4–1.73), MCI (1.8–3.3), and AD (3.43–3.98) also correlates with the disease severity^{10, 11}. As the annualized hippocampal volume

loss measured in our study is higher than the one reported in Alzheimer disease patients, it is possible that treatment-induced hippocampal atrophy might directly explain the very high rate of memory deficits seen in long-term GBM survivors¹⁵. Data from clinical studies has identified severe treatment-induced dementia in a high number of long-term GBM survivors and cancer patients with brain metastasis^{15, 16}. The evidence of such cognitive impairment has encouraged the use of particular AD drugs in brain cancer patients, to combat damaging neurological deficits resulting from the treatment of primary and metastatic brain tumors¹⁷.

Bevacizumab is a VEGF inhibitor with anti angiogenic properties. Animal models have shown that VEGF expression is required for hippocampal neurogenesis involved in learning and memory¹⁸. It has been suggested that VEGF contributes to neuroprotection and neuronal repair in the central nervous system via its role in neurogenesis, long-term potentiation and cerebral blood flow following focal brain ischemia¹⁹. A recent study showed that prolonged treatment with bevacizumab is potentially associated with brain atrophy in malignant glioma patients²⁰. The same study proposes that restricting VEGF may decrease the amount of neuronal repair, neurogenesis, and learning²⁰. We propose that bevacizumab could contribute specifically to hippocampal atrophy by impairing hippocampal neurogenesis and healing of normal brain from surgical trauma, radiation and chemotherapy.

Previous papers report limitations due to resection, hemispheric tumor burden, and length of study, which may have impacted their ability to detect significant changes in the hippocampus over time¹⁴. It is suggested that the investigation into radiation and chemotherapy separately, in addition to novel targeted therapies over a longer period of time with stringent surgical parameters and a larger sample size, may be sufficient enough to determine further brain changes¹⁴. Our study analyzed sagittal cross sections of the hippocampus, imaged by magnetic resonance, over a span of several years beginning at diagnosis. The study detected concerning atrophy rates in glioma patients (8.903%/year) over the course of their entire treatment -- twice the reported rate of AD populations, three times the rate of MCI, and nearly four times the rate of normal aging (see Table 2). The retrospective nature of this study did not allow for concurrent investigation of cognitive impairment in our patients.

In conclusion, this study suggests that hippocampal atrophy is a relatively late phenomenon in the treatment of malignant glioma patients. The overall survival of malignant glioma patients is on the rise, and reached over two years in recent studies²¹ – which potentially exposes the patients to prolonged use of chemotherapy drugs, including bevacizumab. We are currently planning a prospective study to examine the association between the rate of hippocampal atrophy, cognitive impairments and decreased quality of life in malignant glioma patients on active chemotherapy for long periods of time.

Acknowledgments

Funding: This study was supported by the National Institute for Neurological Diseases and Stroke Award number NS072234, by the UCI Cancer Center Award Number P30CA062203 from the National Cancer Institute and by research funds donated by various donors to UC Irvine Neurological Oncology Program.

References

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* 2009; 10:459–466. [PubMed: 19269895]
2. Hilverda K, Bosma I, Heimans JJ, et al. Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. *J Neurooncol.* 2010; 97:89–94. [PubMed: 19718545]
3. Asai A, Matsutani M, Kohno T, et al. Subacute brain atrophy after radiation therapy for malignant brain tumor. *Cancer.* 1989; 63:1962–1974. [PubMed: 2702569]
4. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. *Lancet Neurol.* 2004; 3:159–168. [PubMed: 14980531]
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. *Clin Cancer Res.* 2007; 13:1253–1259. [PubMed: 17317837]
6. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology.* 2008; 70:779–787. [PubMed: 18316689]
7. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. *Proc Natl Acad Sci U S A.* 2002; 99:11946–11950. [PubMed: 12181492]
8. Ng T, Cheung YT, Ng QS, Ho HK, Chan A. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. *Expert Opin Drug Saf.* 2014; 13:83–92. [PubMed: 23931162]
9. Bag AK, Kim H, Gao Y, et al. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. *Journal of Neuro-Oncology.* 2015; 122:585–593. [PubMed: 25711673]
10. Chiang GC, Insel PS, Tosun D, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. *Neurology.* 2010; 75:1976–1981. [PubMed: 20980669]
11. Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. *Neurology.* 2000; 55:484–489. [PubMed: 10953178]
12. Ross TP, Calhoun E, Cox T, Wenner C, Kono W, Pleasant M. The reliability and validity of qualitative scores for the Controlled Oral Word Association Test. *Arch Clin Neuropsychol.* 2007; 22:475–488. [PubMed: 17317094]
13. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med.* 2014; 370:699–708. [PubMed: 24552317]
14. Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. *Neurology.* 2015; 85:683–691. [PubMed: 26208964]
15. Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. *J Neurooncol.* 2003; 63:55–61. [PubMed: 12814255]
16. Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. *Neurology.* 1998; 51:993–999. [PubMed: 9781519]
17. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. *Neurology.* 2004; 62:591–600. [PubMed: 14981176]
18. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. *Brain.* 2009; 132:1067–1077. [PubMed: 19251758]
19. Ridha BH, Anderson VM, Barnes J, et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. *J Neurol.* 2008; 255:567–574. [PubMed: 18274807]

Figure 1.
Representative **Imaging Changes.** T1 Magnetic resonance images of sagittal cross-sections of hippocampus for patient 3 during seven years of treatment.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2. Hippocampal Atrophy

(A) The longitudinal progression of hippocampal volume after start of bevacizumab presented as *percent of hippocampal atrophy* from baseline volume at diagnosis. (B) The longitudinal progression of hippocampal volume after start of bevacizumab presented as *the mean volume (mm³) of hippocampus* at specific time point. (C) The longitudinal

progression of hippocampal volume after start of adjuvant temozolomide presented *as percent of hippocampal atrophy* from baseline volume at diagnosis. **(D)** The longitudinal progression of hippocampal volume after start of adjuvant temozolomide presented as *the mean volume (mm³) of hippocampus* at specific time point. The error bars represent standard error mean (SEM) for each time point. The numbers are (n) patients included at that time point. The “stars” show a significant mean difference from start of a specific chemotherapy (bevacizumab or temozolomide). The “triangles” show a significant mean difference compared to initial diagnosis. (E) Baseline (100%) is start of bevacizumab. The “stars” show a significant mean difference from start of bevacizumab. The “diamonds” show a significant mean difference compared to the previous year. (* p 0.05, ** p 0.01, *** p 0.001; ◆ p 0.05, ◆◆ p 0.01, ◆◆◆ p 0.001).

Table 1

Patient Characteristics. Table of Clinical Variables.

Case	Age	Sex	Dx	Tumor Location (Brain Region)	Adjuvant temozolomide cycles	Bevacizumab duration (months)	Disease duration (years)	Status
1	40	F	AA (R)	Temporal	2	38	3.65	Dead
2	54	F	GBM (R)	Frontal Temporal	0	33	3.05	Dead
3	50	F	GBM (L)	Frontal	3	55	6.32	Dead
4	61	F	GBM (R)	Temporal	7	8	1.75	Dead
5	63	F	GBM (L)	Frontal	12	43	4.51	Alive
6	68	M	GBM (R)	Frontal	1	24	2.54	Alive
7	52	M	AA (L)	Temporal	0	47	6.81	Alive
8	59	M	GBM (R)	Frontal	1	27	2.54	Alive
9	19	M	AA (L)	Frontal	2	40	5.85	Alive
10	55	M	GBM (R)	Parietal	7	22	3.26	Alive
11	74	M	GBM (L)	Temporal	3	37	3.76	Alive
12	64	F	GBM (R)	Frontal	12	15	3.23	Alive
13	43	F	GBM (L)	Occipital	3	30	3.07	Alive

• R and L indicate right or left side location of the tumor in the brain.

Table 2

Published rates of hippocampal atrophy in memory disorders

“Total” represents the reported overall % atrophy for all the patients in study. “Stable” are patients whose health status did not change. “Decliner/Converter” are patients whose health status changed. “Slow P” stands for slow progressor and are patients whose disease progressed slowly. “Fast P” stands for fast progressor and are patients whose disease progressed quickly.

Pathology	Study	Methodology	Imaging	% Annual atrophy			
				Total	Stable	Decliner/Converter	
Normal	Jack, C.R., et al ¹⁶	Cohort	Manual Tracing	1.55			
	Jack, C.R., et al ¹¹	Cohort	Manual Tracing	1.9	1.7	2.8	
	Jack, C.R., et al ¹⁷	Cohort	Manual Tracing		1.4	3.3	
	Schuff, N., et al ¹⁸	Cohort	High-dimensional fluid transformation algorithm	0.3–0.97			
Mild cognitive impairment (MCI)	Jack, C.R., et al ¹¹	Cohort	Manual Tracing	3.0	2.5	3.7	
	Jack, C.R., et al ¹⁷	Cohort	Manual Tracing		1.8	3.3	
	Schuff, N., et al. ¹⁸	Cohort	High-dimensional fluid transformation algorithm	2.0–3.07			
Alzheimers disease (AD)	Jack, C.R., et al ¹⁶	Cohort	Manual Tracing	3.98			
	Jack, C.R., et al ¹¹	Cohort	Manual Tracing	3.5			
	Jack, C.R., et al ¹⁷	Cohort	Manual Tracing		3.0	3.6	
	Ridha, Basil H., et al ¹⁹	Randomized Case Control	Manual Tracing	3.43			
	Schuff, N., et al. ¹⁸	Cohort	High-dimensional fluid transformation algorithm	3.3–5.77			